AbbVie Inc. Stock Performance
AbbVie Inc. shares closed at $250.88, reflecting a single-session decline of 1.32%, per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum over the intermediate term, gaining 19.68% over the trailing three months and 1.63% over the past month. On a twelve-month basis, ABBV has appreciated 8.39%, according to Massive/Polygon data. The stock currently trades above both key moving averages, with the 50-day moving average at $243.10 and the 200-day moving average at $224.87, indicating a structurally positive trend. However, the 14-day relative strength index registers at 40.5, suggesting the stock has pulled back toward the lower end of neutral territory without reaching oversold levels. AbbVie maintains a market capitalization of approximately $410.1 billion. The stock's beta of 0.334 reflects significantly lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume stands at approximately 6.4 million shares.
AbbVie Inc. Valuation Analysis
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a significantly elevated multiple relative to healthcare sector peers, per SID market data. This elevated P/E reflects the earnings impact of acquisition-related amortization and other non-cash charges rather than underlying operational weakness. The company's PEG ratio stands at 1.25, suggesting the valuation is more reasonable when adjusted for expected earnings growth. AbbVie offers a dividend yield of 2.87%, according to SEC filings, underscoring its continued commitment to shareholder returns through its well-established dividend program. Notably, the price-to-book ratio is negative at -126.33, a result of AbbVie's negative shareholders' equity driven by accumulated goodwill impairments and substantial debt taken on during its acquisition strategy, including the $63 billion Allergan deal. Investors evaluating AbbVie's valuation should consider cash-flow-based metrics alongside traditional multiples given the company's unique balance sheet structure within the biopharmaceutical industry.
Smart Money Activity for ABBV
AbbVie Inc. registers a composite smart money score of 54, signaling a neutral overall stance from sophisticated market participants, per SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum confidence and robust accumulation among large fund managers and institutional holders. The insider trading component also scores favorably at 18 out of 25, supported by two insider purchases and zero insider sales recorded over the past 90 days, according to SEC Form 4 filings. This buy-only insider activity suggests corporate officers and directors view the current price level as attractive. Conversely, dark pool activity scores a modest 9.9 out of 25, indicating below-average off-exchange buying pressure. Congressional trading activity is minimal, scoring just 0.8 out of 25, per 13F institutional filings. The divergence between strong institutional and insider conviction versus muted dark pool and congressional interest creates a mixed but net-positive signal. The perfect institutional score is particularly notable, as it reflects broad-based support from the largest allocators in the market.
AbbVie Inc. Earnings Outlook
AbbVie Inc. has delivered a mixed recent earnings track record, per company earnings reports. In the most recent completed quarter reported on February 4, 2026, AbbVie posted earnings per share of $2.71, exceeding the consensus estimate of $2.66 by $0.05. However, the subsequent quarter reported on April 29, 2026, showed EPS of $2.65, narrowly missing the $2.66 estimate by $0.01. The quarter reported on July 31, 2026, reflected a more notable shortfall, with actual EPS of $3.65 coming in $0.12 below the $3.77 consensus estimate. Looking ahead, analyst estimates project EPS of $3.01 for the upcoming reporting period dated April 24, 2026. The pattern of declining beat margins and the most recent miss suggest AbbVie faces increasing difficulty surpassing Wall Street expectations. Analysts continue to monitor the company's revenue diversification efforts as legacy Humira biosimilar competition pressures the top line while newer immunology and oncology assets scale.
Wall Street Analyst Ratings for ABBV
Wall Street analysts maintain a predominantly constructive view on AbbVie Inc., according to SID consensus data. In the most recent round of coverage updates, four out of five analysts reiterated positive ratings. Guggenheim maintained its Buy rating on August 4, 2026, while Cantor Fitzgerald reaffirmed an Overweight stance and Canaccord Genuity reiterated Buy, both on August 3, 2026, per Wall Street analyst reports. Evercore ISI Group upheld its Outperform rating on August 10, 2026. The sole non-bullish voice came from BNP Paribas, which maintained a Neutral rating on August 11, 2026. Notably, none of the five most recent analyst actions involved a downgrade, with all firms reiterating their prior positions. This consistency reflects stable institutional conviction in AbbVie's long-term growth drivers, particularly its Skyrizi and Rinvoq immunology franchises. The four-to-one ratio of bullish versus neutral ratings indicates the sell-side consensus leans firmly positive despite the stock's elevated trailing valuation multiples and recent earnings miss.
